# Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

> **NCT00364286** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Dasatinib (BMS-354825)

## Key facts

- **NCT ID:** NCT00364286
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- Bristol-Myers Squibb

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364286, "Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00364286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*